Selection and evaluation of clinically relevant AAV variants in a xenograft liver model

Leszek Lisowski, Allison P. Dane, Kirk Chu, Yue Zhang, Sharon C. Cunningham, Elizabeth M. Wilson, Sean Nygaard, Markus Grompe, Ian E. Alexander, Mark A. Kay

Research output: Contribution to journalArticle

174 Citations (Scopus)

Abstract

Recombinant adeno-associated viral (rAAV) vectors have shown early promise in clinical trials. The therapeutic transgene cassette can be packaged in different AAV capsid pseudotypes, each having a unique transduction profile. At present, rAAV capsid serotype selection for a specific clinical trial is based on effectiveness in animal models. However, preclinical animal studies are not always predictive of human outcome. Here, in an attempt to further our understanding of these discrepancies, we used a chimaeric human-murine liver model to compare directly the relative efficiency of rAAV transduction in human versus mouse hepatocytes in vivo. As predicted from preclinical and clinical studies, rAAV2 vectors functionally transduced mouse and human hepatocytes at equivalent but relatively low levels. However, rAAV8 vectors, which are very effective in many animal models, transduced human hepatocytes rather poorly-approximately 20 times less efficiently than mouse hepatocytes. In light of the limitations of the rAAV vectors currently used in clinical studies, we used the same murine chimaeric liver model to perform serial selection using a human-specific replication-competent viral library composed of DNA-shuffled AAV capsids. One chimaeric capsid composed of five different parental AAV capsids was found to transduce human primary hepatocytes at high efficiency in vitro and in vivo, and provided species-selected transduction in primary liver, cultured cells and a hepatocellular carcinoma xenograft model. This vector is an ideal clinical candidate and a reagent for gene modification of human xenotransplants in mouse models of human diseases. More importantly, our results suggest that humanized murine models may represent a more precise approach for both selecting and evaluating clinically relevant rAAV serotypes for gene therapeutic applications.

Original languageEnglish (US)
Pages (from-to)382-386
Number of pages5
JournalNature
Volume506
Issue number7488
DOIs
StatePublished - 2014

Fingerprint

Heterografts
Capsid
Liver
Hepatocytes
Animal Models
Clinical Trials
Viral Genes
Transgenes
Gene Library
Hepatocellular Carcinoma
Cultured Cells
Therapeutics
Genes

ASJC Scopus subject areas

  • General

Cite this

Lisowski, L., Dane, A. P., Chu, K., Zhang, Y., Cunningham, S. C., Wilson, E. M., ... Kay, M. A. (2014). Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. Nature, 506(7488), 382-386. https://doi.org/10.1038/nature12875

Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. / Lisowski, Leszek; Dane, Allison P.; Chu, Kirk; Zhang, Yue; Cunningham, Sharon C.; Wilson, Elizabeth M.; Nygaard, Sean; Grompe, Markus; Alexander, Ian E.; Kay, Mark A.

In: Nature, Vol. 506, No. 7488, 2014, p. 382-386.

Research output: Contribution to journalArticle

Lisowski, L, Dane, AP, Chu, K, Zhang, Y, Cunningham, SC, Wilson, EM, Nygaard, S, Grompe, M, Alexander, IE & Kay, MA 2014, 'Selection and evaluation of clinically relevant AAV variants in a xenograft liver model', Nature, vol. 506, no. 7488, pp. 382-386. https://doi.org/10.1038/nature12875
Lisowski L, Dane AP, Chu K, Zhang Y, Cunningham SC, Wilson EM et al. Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. Nature. 2014;506(7488):382-386. https://doi.org/10.1038/nature12875
Lisowski, Leszek ; Dane, Allison P. ; Chu, Kirk ; Zhang, Yue ; Cunningham, Sharon C. ; Wilson, Elizabeth M. ; Nygaard, Sean ; Grompe, Markus ; Alexander, Ian E. ; Kay, Mark A. / Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. In: Nature. 2014 ; Vol. 506, No. 7488. pp. 382-386.
@article{f7595dcd1a834c9d94b913727f080ae0,
title = "Selection and evaluation of clinically relevant AAV variants in a xenograft liver model",
abstract = "Recombinant adeno-associated viral (rAAV) vectors have shown early promise in clinical trials. The therapeutic transgene cassette can be packaged in different AAV capsid pseudotypes, each having a unique transduction profile. At present, rAAV capsid serotype selection for a specific clinical trial is based on effectiveness in animal models. However, preclinical animal studies are not always predictive of human outcome. Here, in an attempt to further our understanding of these discrepancies, we used a chimaeric human-murine liver model to compare directly the relative efficiency of rAAV transduction in human versus mouse hepatocytes in vivo. As predicted from preclinical and clinical studies, rAAV2 vectors functionally transduced mouse and human hepatocytes at equivalent but relatively low levels. However, rAAV8 vectors, which are very effective in many animal models, transduced human hepatocytes rather poorly-approximately 20 times less efficiently than mouse hepatocytes. In light of the limitations of the rAAV vectors currently used in clinical studies, we used the same murine chimaeric liver model to perform serial selection using a human-specific replication-competent viral library composed of DNA-shuffled AAV capsids. One chimaeric capsid composed of five different parental AAV capsids was found to transduce human primary hepatocytes at high efficiency in vitro and in vivo, and provided species-selected transduction in primary liver, cultured cells and a hepatocellular carcinoma xenograft model. This vector is an ideal clinical candidate and a reagent for gene modification of human xenotransplants in mouse models of human diseases. More importantly, our results suggest that humanized murine models may represent a more precise approach for both selecting and evaluating clinically relevant rAAV serotypes for gene therapeutic applications.",
author = "Leszek Lisowski and Dane, {Allison P.} and Kirk Chu and Yue Zhang and Cunningham, {Sharon C.} and Wilson, {Elizabeth M.} and Sean Nygaard and Markus Grompe and Alexander, {Ian E.} and Kay, {Mark A.}",
year = "2014",
doi = "10.1038/nature12875",
language = "English (US)",
volume = "506",
pages = "382--386",
journal = "Nature",
issn = "0028-0836",
publisher = "Nature Publishing Group",
number = "7488",

}

TY - JOUR

T1 - Selection and evaluation of clinically relevant AAV variants in a xenograft liver model

AU - Lisowski, Leszek

AU - Dane, Allison P.

AU - Chu, Kirk

AU - Zhang, Yue

AU - Cunningham, Sharon C.

AU - Wilson, Elizabeth M.

AU - Nygaard, Sean

AU - Grompe, Markus

AU - Alexander, Ian E.

AU - Kay, Mark A.

PY - 2014

Y1 - 2014

N2 - Recombinant adeno-associated viral (rAAV) vectors have shown early promise in clinical trials. The therapeutic transgene cassette can be packaged in different AAV capsid pseudotypes, each having a unique transduction profile. At present, rAAV capsid serotype selection for a specific clinical trial is based on effectiveness in animal models. However, preclinical animal studies are not always predictive of human outcome. Here, in an attempt to further our understanding of these discrepancies, we used a chimaeric human-murine liver model to compare directly the relative efficiency of rAAV transduction in human versus mouse hepatocytes in vivo. As predicted from preclinical and clinical studies, rAAV2 vectors functionally transduced mouse and human hepatocytes at equivalent but relatively low levels. However, rAAV8 vectors, which are very effective in many animal models, transduced human hepatocytes rather poorly-approximately 20 times less efficiently than mouse hepatocytes. In light of the limitations of the rAAV vectors currently used in clinical studies, we used the same murine chimaeric liver model to perform serial selection using a human-specific replication-competent viral library composed of DNA-shuffled AAV capsids. One chimaeric capsid composed of five different parental AAV capsids was found to transduce human primary hepatocytes at high efficiency in vitro and in vivo, and provided species-selected transduction in primary liver, cultured cells and a hepatocellular carcinoma xenograft model. This vector is an ideal clinical candidate and a reagent for gene modification of human xenotransplants in mouse models of human diseases. More importantly, our results suggest that humanized murine models may represent a more precise approach for both selecting and evaluating clinically relevant rAAV serotypes for gene therapeutic applications.

AB - Recombinant adeno-associated viral (rAAV) vectors have shown early promise in clinical trials. The therapeutic transgene cassette can be packaged in different AAV capsid pseudotypes, each having a unique transduction profile. At present, rAAV capsid serotype selection for a specific clinical trial is based on effectiveness in animal models. However, preclinical animal studies are not always predictive of human outcome. Here, in an attempt to further our understanding of these discrepancies, we used a chimaeric human-murine liver model to compare directly the relative efficiency of rAAV transduction in human versus mouse hepatocytes in vivo. As predicted from preclinical and clinical studies, rAAV2 vectors functionally transduced mouse and human hepatocytes at equivalent but relatively low levels. However, rAAV8 vectors, which are very effective in many animal models, transduced human hepatocytes rather poorly-approximately 20 times less efficiently than mouse hepatocytes. In light of the limitations of the rAAV vectors currently used in clinical studies, we used the same murine chimaeric liver model to perform serial selection using a human-specific replication-competent viral library composed of DNA-shuffled AAV capsids. One chimaeric capsid composed of five different parental AAV capsids was found to transduce human primary hepatocytes at high efficiency in vitro and in vivo, and provided species-selected transduction in primary liver, cultured cells and a hepatocellular carcinoma xenograft model. This vector is an ideal clinical candidate and a reagent for gene modification of human xenotransplants in mouse models of human diseases. More importantly, our results suggest that humanized murine models may represent a more precise approach for both selecting and evaluating clinically relevant rAAV serotypes for gene therapeutic applications.

UR - http://www.scopus.com/inward/record.url?scp=84894242894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894242894&partnerID=8YFLogxK

U2 - 10.1038/nature12875

DO - 10.1038/nature12875

M3 - Article

C2 - 24390344

AN - SCOPUS:84894242894

VL - 506

SP - 382

EP - 386

JO - Nature

JF - Nature

SN - 0028-0836

IS - 7488

ER -